The company's revenue jumped 77% in Q3 to reach $401.6 million in Q3 2024, alongside a net income of $75.6 million. It now ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Hims & Hers Health's stock dropped 25% due to Amazon’s competition. Learn why HIM stock's 38% upside and strong growth make ...

Berkshire Hathaway buys Domino’s Pizza stake, Amazon makes move into cheaper drugs, and more news to start your day.

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...

A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

GLP-1RA prescription trends, real-world effectiveness, and predictors for access and rationing were highlighted at ...

With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years ...

The following is a summary of “Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...